Latest Ratios: P/E Ratio -2.3x · EV/EBITDA N/A · ROE -196.9%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $34M | $92M | $250M | $413M | $1.0B | $11.8B | $23.6B | — | — |
| Enterprise Value | $21M | $79M | $221M | $288M | $948M | $11.7B | $23.4B | — | — |
| P/E Ratio → | -2.27 | — | — | — | — | — | — | — | — |
| P/S Ratio | 15.77 | 42.14 | 63.27 | 26.59 | 73.13 | 2713.26 | — | — | — |
| P/B Ratio | 1.03 | 1.72 | — | 4.48 | 9.79 | 64.02 | 107.37 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 36.17 | 56.01 | 18.57 | 68.18 | 2673.72 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.5% | 57.5% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | -4024.9% | -4024.9% | -2259.9% | -567.5% | -701.7% | -2943.8% | — | — | — |
| Net Profit Margin | -1106.7% | -1106.7% | -3326.0% | -564.6% | -690.6% | -2944.1% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -196.9% | -196.9% | -415.8% | -89.5% | -66.6% | -63.4% | -139.9% | — | — |
| ROA | -30.5% | -30.5% | -118.4% | -58.8% | -50.3% | -51.3% | -52.7% | -41.1% | -12.9% |
| ROIC | -163.0% | -163.0% | — | -5005.3% | -308.2% | -768.9% | -579.4% | — | — |
| ROCE | -152.1% | -152.1% | -101.3% | -73.1% | -63.0% | -59.5% | -53.2% | -46.4% | -13.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | — | 0.12 | 0.12 | 0.08 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.24 | — | -1.35 | -0.66 | -0.93 | -0.94 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -10.28 | — | — |
Net cash position: cash ($18M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.90 | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
| Quick Ratio | 3.90 | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
| Cash Ratio | 3.67 | 3.67 | 2.62 | 5.68 | 3.80 | 4.90 | 8.04 | 8.52 | 12.13 |
| Asset Turnover | — | 0.02 | 0.06 | 0.10 | 0.09 | 0.02 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $10M | $6M | $25M | $43M | $40M | $34M | $22M | $21M |
Imminent capital dilution risk
As reported in financial statements, the company's P/S ratio of 15.77 appears to be driven more by the scarcity of revenue-generating milestones than by fundamental growth, suggesting that investors are pricing the stock based on speculative pipeline potential rather than any established, recurring commercial valuation metrics.
The current P/B ratio of 1.03 indicates that the market is valuing the company near its liquidation value, which is typical for clinical-stage firms with limited cash runways. This valuation level suggests that the market has largely discounted the platform's long-term potential in favor of immediate concerns regarding the company's ability to fund its ongoing R&D programs.
Based on historical data, the ROIC has trended toward -87.1% in 2026Q1, reflecting a severe erosion of invested capital as the firm prioritizes high-cost clinical trials over the generation of positive returns, a trend that warrants further investigation by investors monitoring the company's long-term viability.
The persistent negative ROIC highlights the structural challenge of a business model that requires massive upfront investment without a clear path to near-term profitability. This decay in capital efficiency suggests that every dollar of equity raised is being consumed by R&D rather than compounding into sustainable value for shareholders.
According to recent quarterly filings, the current ratio has compressed to 2.56 in 2026Q1 from a peak of 7.56 in 2025Q1, signaling that the company's ability to cover short-term obligations is rapidly diminishing as cash reserves are depleted by intensive clinical development and operational overhead.
While a current ratio of 2.56 might appear adequate in isolation, the lack of recurring revenue means that this liquidity is essentially a finite pool that is being drained at an accelerating rate. Investors should monitor the cash burn trajectory closely, as the current liquidity position may necessitate dilutive financing in the near term to maintain operations.
As evidenced by the reported TTM P/E of -2.27, the use of price-to-earnings ratios is fundamentally misapplied to this business model, as the metric obscures the reality that the company is in a pre-commercial, cash-burning phase where earnings are not a meaningful indicator of operational health.
Investors should instead focus on cash runway and clinical milestone progress, as P/E ratios in this context provide no insight into the company's ability to reach a functional cure or secure future partnerships. Relying on earnings-based valuation for a clinical-stage biotech risks misinterpreting a lack of profitability as a failure of the underlying technology rather than a standard stage-gate reality.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALGS stock.
Aligos Therapeutics, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
Aligos Therapeutics, Inc.'s return on equity (ROE) is -196.9%. The historical average is -162.0%.
Based on historical data, Aligos Therapeutics, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Aligos Therapeutics, Inc. has 57.5% gross margin and -4024.9% operating margin.